The Synthetic Heteroarotinoid SHetA2 Induces Apoptosis in Squamous Carcinoma Cells through a Receptor-independent and Mitochondria-dependent Pathway

Kyung-Hee Chun, Doris M. Benbrook, K. Darrell Berlin, Waun Ki Hong, and Reuben Lotan

Department of Thoracic/Head and Neck Oncology, The University of Texas M. D. Anderson Cancer Center, Houston, Texas 77030 [K-H.C., W. K. H., R. L.]; Department of Obstetrics and Gynecology, and Department of Biochemistry and Molecular Biology, The University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma 73190 [D. M. B.]; and The Department of Chemistry, Oklahoma State University, Stillwater, Oklahoma 74078 [K. D. B.]

ABSTRACT

Retinoids that regulate cell growth, differentiation, and apoptosis have shown promising results in preclinical studies and in a few clinical trials of cancer chemoprevention and therapy. However, the clinical use of retinoids is limited by resistance of certain malignant cells to their antitumor effects and by side effects. To identify more potent retinoids, we examined the effects of heteroarotinoids (Hets), new synthetic retinoids with reduced toxicity, on the growth of human head and neck squamous cell carcinoma (HNSCC) lines. Six Hets with different retinoic acid receptor activation potentials were found to exhibit distinct efficacies. The most potent among the Hets examined, SHetA2, [N-(4-nitrophenyl)amino][2,2,4,4-tetramethyl thiochroman-6-yl]amino]methane-1-thione, was more effective than either all-trans- or 9-cis-RA. The growth of UMSCC38, the most sensitive among the eight HNSCC cell lines examined, was suppressed by SHetA2 in a dose- and time-dependent fashion. SHetA2-induced apoptosis was observed in UMSCC38 cells was comparable with N-(4-hydroxyphenyl)retinamide (4HPR). Reactive oxygen species (ROS) generation in the UMSCC38 cells was increased by SHetA2, and this effect was suppressed by the antioxidant butylated hydroxyanisol, which also suppressed SHetA2-induced apoptosis. SHetA2 suppressed mitochondrial permeability transition and enhanced cytochrome c release from mitochondria. Both of these effects were prevented by cyclosporin A, which also decreased SHetA2-induced apoptosis. SHetA2 increased caspase-3-like activity, and a caspase-3 inhibitor diminished SHetA2-induced apoptosis. Several retinoid receptor antagonists failed to prevent apoptosis induction by SHetA2. These results demonstrate that SHetA2 is a potent, receptor-independent, apoptosis inducer that acts on the mitochondria in HNSCC cells. Further investigation of the potential of SHetA2 in prevention and therapy of HNSCC is warranted also because of much lower toxicities compared with receptor active retinoids.

INTRODUCTION

Retinoids, natural and synthetic vitamin A analogues, have demonstrated potential in the chemoprevention of a variety of cancers in animal models (1) and in humans at increased risk for developing primary or secondary cancers (2–4). Certain retinoids can also inhibit the growth, induce the differentiation, or enhance apoptosis of fully malignant cells in vitro (5) and in vivo (6–8). Head and neck premalignant and malignant cells are susceptible to retinoid chemopreventive (2, 3) and therapeutic (7–9) effects. In the present study, we demonstrate the ability of some Hets to induce apoptosis in HNSCC cell lines, and we shed light on some aspects of the mechanism of apoptosis induction. Specifically, we show that the induction of apoptosis is independent of retinoid receptor signaling pathway and that it involves changes in mitochondrial permeability transition and cytochrome c release following activation of caspases 3.

MATERIALS AND METHODS

Retinoids. The Hets were synthesized as published (19, 21). SHet50 is a receptor pan-agonist, Ohet72 is specific for the RXRs, whereas SHetA2, SHetA3, and SHetA4 do not activate any of the receptors when used at doses up to 10 μM (Fig. 1). ATRA was obtained from Dr. Werner Bollag (F. Hoffmann-La Roche, Basel, Switzerland). AGN 193109 [a RAR-α, -β, and -γ antagonist (23)], was obtained from Dr. R. Chandraratna (Allergan, Irvine, CA). LG100754, a RXR antagonist (24), was obtained from Dr. R. Heyman.

Received 9/16/02; accepted 4/28/03.

1 The abbreviations used are: RA, retinoic acid; ATRA, all-trans-RA; BHA, butylated hydroxyanisol; DCF-DA, 5,6-carboxy-2’,7’-dichlorofluorescein diacetate; DIOC6(3,3’-dihexyloxacarbocyanine iodide; Het, heteroarotinoid; HNSCC, head and neck squamous cell carcinoma; MPT, membrane permeability transition; RAR, RA receptor; ROS, proliferation, inhibit the formation of colonies in semisolid agarose, and decrease the growth of HNSCC multicellular spheroids (10, 11). In addition, retinoids suppress the expression of several squamous differentiation markers and inhibit cornified envelope formation (10, 12).

Many HNSCC cell lines exhibit relative resistance to the growth-inhibitory effects of ATRA and 9-cis-RA, although some synthetic analogues are quite potent (13). For example, 4HPR is an effective inducer of apoptosis, albeit at high (>5 μM) concentrations (14).

The clinical application of ATRA is limited by a number of side effects (2). Likewise, 4HPR has a significant side effect (night blindness) resulting mainly from reduction in circulating retinol levels (15). Therefore, new retinoids are being synthesized and characterized with the hope of improving their antitumor and chemopreventive efficacy. The toxicity and teratogenicity of retinoids are associated with the activation of nuclear RARs and RXRs that act as transcription factors (16–18). Thus retinoid-related molecules, which inhibit the growth of cancer cells or induce apoptosis by receptor-independent molecules, may be devoid of side effects.

Certain retinoids belonging to the class of Hets have demonstrated anticancer activity as well as low toxicity (19–22). Hets have demonstrated growth-inhibitory activity against carcinoma cell lines derived from cervix, vulva, ovary, and HNSCC tumors (20). Some Hets caused a reduction in tumor size in a xenograft model of human HNSCC cell line UMSCC38 in nude mice (21). Recently, some receptor-activating and receptor-independent Hets were found to induce differentiation and apoptosis in organotypic cultures of ovarian carcinoma (22). Although this indicates that receptor activation is not required for apoptosis, the mechanism(s) that underlie the induction of apoptosis in cancer cells by Hets has not been investigated.

In the present study, we demonstrate the ability of some Hets to induce apoptosis in HNSCC cell lines, and we shed light on some aspects of the mechanism of apoptosis induction. Specifically, we show that the induction of apoptosis is independent of retinoid receptor signaling pathway and that it involves changes in mitochondrial permeability transition and cytochrome c release following activation of caspases 3.
HET-INDUCED APOPTOSIS IN HNSCC CELLS

<table>
<thead>
<tr>
<th>Retinoid</th>
<th>Structure</th>
<th>Receptor activation (EC50, nM)</th>
<th>RAβx</th>
<th>RARα</th>
<th>RAβγ</th>
<th>RXRa</th>
<th>RXRB</th>
<th>RXRA</th>
<th>RXRB</th>
</tr>
</thead>
<tbody>
<tr>
<td>ATRA</td>
<td><img src="ATRA.png" alt="ATRA" /></td>
<td>350 80 10 900 1400 1100</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>9-cis-RA</td>
<td><img src="9-cis-RA.png" alt="9-cis-RA" /></td>
<td>191 50 45 100 200 140</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>4HPR</td>
<td><img src="4HPR.png" alt="4HPR" /></td>
<td>&gt;20,000 &gt;20,000 5,000 &gt;20,000 ND ND</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ShetA2</td>
<td><img src="ShetA2.png" alt="ShetA2" /></td>
<td>No transactivation at 10,000</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ShetA3</td>
<td><img src="ShetA3.png" alt="ShetA3" /></td>
<td>No transactivation at 10,000</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ShetA4</td>
<td><img src="ShetA4.png" alt="ShetA4" /></td>
<td>No transactivation at 10,000</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Shet50</td>
<td><img src="Shet50.png" alt="Shet50" /></td>
<td>225 1004 152 84 68 302</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ShetA19</td>
<td><img src="ShetA19.png" alt="ShetA19" /></td>
<td>No transactivation at 10,000</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>OHet72</td>
<td><img src="OHet72.png" alt="OHet72" /></td>
<td>&gt;10,000 &gt;10,000 &gt;10,000 294 1897 42</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>AGN193109</td>
<td><img src="AGN193109.png" alt="AGN193109" /></td>
<td>RAR antagonist 3 2 2 3 &gt;10,000 &gt;10,000 &gt;10,000</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>LG100754</td>
<td><img src="LG100754.png" alt="LG100754" /></td>
<td>RXRβ antagonist 3 &gt;1000 &gt;1000 &gt;1000 3.4 10 9.7</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Fig. 1. Structure of the retinoids used in this study. *a* Analyzed by transcriptional activation of reporter constructs in cells transfected with individual receptors (19–22) or *b* binding to receptors (23, 24).

(Ligand Pharmaceuticals, Inc., San Diego, CA). The chemical structures and receptor selectivity of these retinoids are presented in Fig. 1.

**Cell Lines and Cell Culture.** Human HNSCC cell lines UMCC17A, UMCC17B, UMCC22B, and UMCC36 cell lines were obtained from Dr. T. Carey (University of Michigan, Ann Arbor, MI). HNSCC cell lines MDA886Ln, 1186, and 1483 were provided by Dr. P. G. Sacks (New York University College of Dentistry, New York, NY). SqCCY1 cells were provided by Dr. M. Reiss (Yale University, New Haven, CT). These cells were grown in monolayer culture in a 1:1 (v/v) mixture of DMEM and Ham’s F12 medium, supplemented with 5% fetal bovine serum and antibiotics at 37°C in a humidified atmosphere consisting of 95% air and 5% CO₂.

**Treatment with Hets and Determination of Cell Survival.** Cells were seeded at a density of 3000 cells/well in 96-well tissue culture plates. After 24 h, cells were treated with different concentrations of retinoids. Control cultures received the same amount of DMSO (final concentrations, 0.01–0.1%) as did the treated cultures. Cell numbers were estimated on days 1, 2, and 3 by using the SRB assay as described in detail previously (13). The percentage of growth inhibition was calculated by using the equation: % growth inhibition = [(A – At/Ac) × 100], where At and Ac represent the absorbance in treated and control cultures, respectively. IC₅₀, the drug concentration causing a 50% cell growth inhibition, was determined by interpolation of the dose-response curve.

**Detection of Apoptosis.** Cells were plated on 10-cm-diameter dishes, and, after 24 h, they received either DMSO or retinoids dissolved in DMSO. After 1, 2, and 3 days of treatment, cells were harvested by a brief trypsinization and were counted. APO-Direct TUNEL kit (Phoenix Flow Systems, Inc., San Diego, CA) was used following the manufacturer’s protocol to label DNA fragments with 3’-hydroxyl ends. In addition, Annexin V-FITC Apoptosis Detection kit (Oncogene Research Products, Cambridge, MA) was also used following the manufacturer’s protocol to label externalized phospholipid. Flow cytometric analysis was conducted using a Coulter EPICS Profile II flow cytometer (Coulter Corp., Miami, FL) equipped with a 488-nm argon laser. Approximately 10,000 events (cells) were evaluated for each sample. Gating of control nonapoptotic populations (cells treated with DMSO) was used as a reference to compare with treatments with retinoids. An internal control, (HL-60 cells treated with camptothecin to induce apoptosis) provided in the apoptosis detection kit, was also used to ensure that the TUNEL reaction was occurring during the staining procedure.

**Assay of Generation of ROS.** The net intracellular generation of ROS was measured by using the oxidation-sensitive fluorescent dye DCF-DA (Molecular Probe, Eugene, OR) as described previously (25, 26). Briefly, Cells were seeded in 6-well plates (10000 cells/well). After 24 h, they were treated with DCF-DA without (control) or with 10 μM of different retinoids and with a mixture of ShetA2 and BHA. The cells were maintained at 37°C, and the fluorescence (excitation at 485 nm, emission at 538 nm) was measured at 30-min intervals. Three wells were used for each control or treatment analysis, and the mean ± SD was determined.

**Assay for Detection of MPT.** Induction of MPT was evaluated as described previously (27). Briefly, after treatment with different agents, both the floating and attached UMCC38 cells were collected by trypsinization, and then were incubated with 50 nm DiOC₆ for 15 min at 37°C. A positive control for transmembrane potential loss was obtained by incubation with the uncoupler carbonylcyanide m-chlorophenylhydrazine (50 μM), a protonophore, which disrupts transmembrane potential. The cells were then analyzed using a cytometer (Facsccaliber, excitation at 488 nm, emission at 552 nm). At least 10,000 events were collected per sample. The suppression of transmembrane potential is represented as a shift of the fluorescence peak to lower levels. The percentage of suppression = (Y – X)/Y × 100, where X and Y correspond to the observed percentage of MPT in untreated (Y) and ShetA2-treated (X) samples. The percentage of cells in the lower fluorescence category was plotted in graphs.

**Assay for Detection of Cytochrome c Release from Mitochondria by Western Blotting.** Semiconfluent cultures of UMCC38 cells were treated with 10 μM different retinoids in 10-cm-diameter plates at 37°C for 24 h. At the end of incubation, medium-containing floating cells and attached cells were harvested by trypsinization. Cell suspensions containing both the floating and the attached cells were subjected to centrifugation at 200 × g for 5 min. After resuspension in 1 ml of buffer I [250 μM sucrose, 30 μM Tris, 1 μM EDTA (pH 7.4)], the cells were transferred to microcentrifuge tubes and were placed on ice. Then the cells were centrifuged in a microcentrifuge at 1000 × g for 1 min. Thirty μl of buffer I, supplemented with leupeptin (1 μg/ml), pepstatin (1 μg/ml), and aprotinin (1 μg/ml), were used to suspend the cells. The cells were then disrupted by homogenization on ice in a 0.3-ml Kontes Dounce homogenizer with 15 strokes of B pestle. The homogenate was subjected to centrifugation at 16,000 × g for 1 min, and then the supernatant was collected and subjected to another centrifugation at 16,000 × g for 30 min. The supernatant extract (cytosolic fraction) and the resulting pellets containing mitochondria (mitochondrial fraction) were frozen at −80°C. Samples containing 25 μg of protein from both fractions were loaded on 12% polyacrylamide gel. After electrophoresis, the proteins were transferred to nitrocellulose membrane (Amersham Life Science, Arlington Heights, IL). After inhibiting nonspecific binding sites with 5% (w/v) skim milk, the membrane was incubated with affinity-purified anti-cytochrome c antibody 7H8.22C12 (PharMingen, San Diego, CA) diluted 1:1000 in 1% (v/v) dried milk in 0.2% (v/v) Tween 20 containing PBS (PBST) for 1 h at room temperature. The membrane was then washed three times in PBST and incubated with rabbit antinouse IgG-HRP-conjugated antibody (DAKO, Carpinteria, CA) and was diluted 1:2000 in 1% (v/v) dried milk in PBST for 1 h at room temperature. The membrane was then washed four times with PBST, stained with enhanced chemiluminescence reagents from Amersham according to the supplier’s instructions, dried, and exposed briefly to X-ray film. The percentage of cytochrome c content was calculated by using the equation: % cytochrome c content = [A/(A + B)] × 100, where A and B represent the relative density of Western blotting protein bands of the cytosolic and pellet fractions, respectively.

**Assay for Caspase-3-like Protease.** Caspase-3-like protease activity was measured by a modification of the method described previously (26). Briefly,
**RESULTS**

**Differential Effects of Hets on the Survival of UMSCC38 Cells.**

We have chosen to use the HNSCC cell line UMSCC38 to explore the mechanism of action of Hets because these cells have been found to be sensitive to some Hets in a xenograft model in nude mice (21). Initially, we examined the effects of treating the cells for 72 h with six different Hets and three retinoids at a concentration of 10 μM (Figs. 1 and 2A). Among the six Hets examined, two (SHetA2 and SHetA19) were found to be more potent than the natural RAs (ATRA and 9-cis-RA) in decreasing the survival of UMSCC38 cells, whereas the other four were less potent. SHetA2 was as effective as the potent pro-apoptotic retinoid 4HPR (Fig. 2A). The effects of these retinoids on cell survival were dose dependent and time dependent (Fig. 2B and C). Decreased cell survival was noticed after 72 h of treatment with concentrations as low as 1 μM for SHetA2 and SHetA19. These two Hets were also effective after shorter treatment (e.g., 24–48 h; Fig. 2C).

**Induction of Apoptosis in UMSCC38 Cells by SHetA2.**

Apoptosis was determined after treatment with SHetA2 by the TUNEL assay as shown in Fig. 3A. Whereas ATRA induced apoptosis in <10% of the cells after a 72 h-treatment (Fig. 3A), SHetA2 induced apoptosis in 47.5% of the cells after a 24 h-treatment, 72.7% after 48-h treatment, and almost 100% of the total cell population after a 72-h treatment (Fig. 3, A and B). Observations under the microscope revealed that the UMSCC38 cells did not detach even after 72 h of exposure to SHetA2, and they appeared to be intact and did not fragment into apoptotic bodies. Using another apoptosis detection method, the Annexin V binding assay, we confirmed the ability of SHetA2 to induce apoptosis (Figs. 3, C and D). 4HPR (10 μM) induced 12.6% of necrosis and 14.1% of late stage of apoptosis after a 24-h treatment, whereas ATRA was considerably less effective (Fig. 3, C and D). In contrast, SHetA2 induced early-stage apoptosis (8.6%) and late-stage apoptosis (33.8%), but not necrosis (2.9%) after a 24-h treatment (Fig. 3C). Among other Hets, SHetA19 was also effective in inducing both early and late stage of apoptosis whereas the other four Hets were ineffective (Fig. 3C).

The proapoptotic effect of SHetA2 was not restricted to UMSCC38, as indicated by our finding that seven other HNSCCs were sensitive to treatment with 10 μM SHetA2 (Fig. 4, A and B). SHetA2 was more potent than ATRA in the induction of apoptosis in eight HNSCC cell lines (Fig. 4B).

**Apoptosis Induced by SHetA2 Is Independent of Retinoid Receptor-mediated Pathway.**

The Hets used in this study included four that exhibited no receptor activation capability, one that was specific for activating RARs, and one that was specific for both RARs and RXRs (Fig. 1). SHetA2 did not transactivate any of the retinoid receptors at concentrations up to 10 μM (Fig. 1). Indeed, neither the pan-RAR-specific antagonist AGN193109 (40 μM) nor the pan-RXR-specific antagonist LG100754 (20 μM) blocked apoptosis induced by SHetA2 (Fig. 4C). Thus, we concluded that apoptosis induced by SHetA2 is independent of activation of RARs or RXRs in the UMSCC38 cells.

**UMSCC38 Cells Accumulate in the S and G2-M Phases of the Cell Cycle after Treatment with SHetA2.**

Examination of cell cycle distributions in UMSCC38 cells treated with 10 μM SHetA2 revealed that cells were shifted from the G0 to the S and G2-M phases after 24 and 48 h compared with DMSO-treated control cells (Fig. 5). In 48-hr treated cultures, the increase in G2-M was twice as high as at 24 h, mostly because of a further decrease in cells in G0. We did not observe the accumulation of cells in a sub-G1 compartment expected from apoptotic cells. The reason may be that the cells had undergone DNA fragmentation but did not form apoptotic bodies therefore the majority of the signals recorded by the flow cytometer was of cells in G1, S phase, or G2-M, not sub-G1.

**Treatment of UMSCC38 Cells with SHetA2 Increases Generation of ROS, Suppresses Mitochondrial Permeability Transition, and Induces Cytochrome c Release from Mitochondria.**

The ability of retinoids, such as 4HPR, to induce apoptosis independent of receptor activation has been ascribed in part to induction of ROS (14, 22–27). Therefore, we explored whether SHetA2 shares a similar mechanism. SHetA2 increased the generation of intracellular ROS in UMSCC38 cells within 60 min after treatment. A linear and time-dependent increase in the ROS generation rate was observed up to 240 min (Fig. 6A). Under the same conditions, ATRA caused a gradual but small increase in ROS generation, whereas 4HPR induced ROS generation more effectively than SHetA2. The increase of ROS by SHetA2 treatment was inhibited by cotreatment with the antioxidant BHA (Fig. 6A). Furthermore, BHA was able to suppress induction of...
apoptosis by SHetA2 (Fig. 6B), suggesting that ROS generation was important for apoptosis induction by SHetA2.

Increased levels of ROS can lead to alterations in the mitochondrial membrane potential followed by the release of caspase-activating factors, such as cytochrome c. A kinetic analysis of the uptake of the potential sensitive dye DiOC6 (25) in SHetA2 treated cells, which is indicative of MPT, demonstrated a time-dependent MPT suppression beginning at 6 h after treatment (Fig. 6C). CsA, the reference inhibitor of MPT (28), prevented the suppression of mitochondrial depolarization by SHetA2 in UMSCC38 cells (Fig. 6D).

The suppression of MPT by SHetA2 treatment of UMSCC38 cells was accompanied by the release of cytochrome c into the cytoplasm (Fig. 6E). This event was blocked by CsA (Fig. 6E). Moreover, the two MPT inhibitors CsA and TFP (27, 29), suppressed induction of apoptosis by SHetA2 treatment (Fig. 6F).

**Activation of Caspase-3 by SHetA2 Treatment.** To investigate additional downstream steps in the apoptosis pathway induced by SHetA2, we tested the activation of caspase-3 in UMSCC38 cells using both a Western blotting and a fluorescent substrate assay. Caspase-3-like activity was increased efficiently and time dependently after SHetA2 treatment (Fig. 7A). Procaspase 3 level decreased after treatment, indicating its activation, and, indeed, an analysis of caspase-3 activity has shown an increase cleavage of a synthetic substrate (Fig. 7A, bottom panel). The caspase-3 inhibitor, Ac-DEVD-CHO, inhibited SHetA2-induced apoptosis in UMSCC38 cells (Fig. 7B).

**DISCUSSION**

The majority of retinoids used in clinical trials to date have exhibited dose-limiting side effects (30–32). Therefore, considerable efforts have been invested in the development of synthetic mimics of RA, which exert similar biological effects but exhibit lower toxicity than RA. One group of retinoids prepared for this purpose is the Hets (33–35). Hets have been defined as retinoids possessing one aromatic ring and at least one heteroatom (e.g., O, S, NR) in the partially saturated ring. A few members of this group exhibited considerable anticancer activity (19–22). Inclusion of the heteroatom in the ring...
cells were exposed to even 1 μM HPR and found that SHetA2 was the most potent among all of these Hrets with those of the natural ATRA and 9-cis-RA, induces apoptosis. Initially, we compared the activities of six Hrets to investigate the mechanism of action of this Het. Because the UMSSC38 cells were found to be the most sensitive to SHetA2 among eight different HNSCC cell lines and had also shown sensitivity to Hets in vitro (21), we chose these cells for additional studies on the SHetA2 mechanism of apoptosis induction. The apoptosis was confirmed by two independent assays, the TUNEL assay and the Annexin V assay. The latter assay demonstrated also that SHetA2 was more potent than 4HPR, a potent proapoptotic retinoid (36, 37), in inducing apoptosis in the UMSSC38 cells. The exposure of these cells to SHetA2 also altered the cell cycle distribution such that the proportion of cells in the G1 phase decreased and that in the S and G2-M phases increased. There are several examples in the literature of agents that can cause cells to accumulate in G2-M and induce apoptosis. Such agents include CD437 (38), vinorelbine (39), and arsenic trioxide (40).

SHetA2 does not activate nuclear retinoid receptors in the mechanism of apoptosis induction by SHetA2 in UMSSC38 cells by demonstrating that SHetA2 increases the proportions of cells in the S phase and G2-M phase of the cell cycle in UMSSC38 cells. Cells were grown with or without 10 μM SHetA2. After 24 or 48 h, cells were harvested and analyzed using a flow cytometer for DNA contents distribution after propidium iodide staining as described in “Materials and Methods.” Results represent two independent experiments. Cells with sub-G1 DNA content were excluded from analysis by gating to obtain cell cycle distribution of cells without extensive DNA degradation.

has been shown to decrease the toxicity 100-fold in an animal model (19).

Zacheis et al. (21) demonstrated that selected Hets inhibit cell proliferation and suppress tumor growth in a xenograft model of HNSCC UMSSC38 cells in nude mice, with no significant toxic effects. SHetA2 did not induce apoptosis in normal ovarian and endometrial cells in vitro and exhibited no toxicity to normal tissues in vivo in an animal model in which tumor inhibition was clearly observed.4

The active Hrets exhibited specificity for both RAR and RXR or for RAR only and also suppressed the activity of the activator protein 1 (AP-1) transcription factor. Although the effects of the Hrets on apoptosis had not been investigated, the marked regression of established tumors in vivo (21) suggested that apoptosis could account for some of the antitumor effects. Recent studies have demonstrated that certain Hets can decrease the growth fraction of ovarian carcinoma cells in organotypic cultures by inducing differentiation or apoptosis (22). Moreover, some Hets were found to induce apoptosis in ATRA-resistant HL60 myeloid leukemia cells (33). However, the mechanism(s) by which Hets induce apoptosis has remained unexplored.

In the present study, we have partially elucidated for the first time some aspects of the mechanisms by which a potent proapoptotic Het, SHetA2, induces apoptosis. Initially, we compared the activities of six Hets with those of the natural ATRA and 9-cis-RA and the synthetic 4HPR and found that SHetA2 was the most potent among all of these retinoids in decreasing the survival of UMSSC38 cells by 50% when cells were exposed to even 1 μM for 72 h. This effect was found to be the result of apoptosis induction. Therefore, subsequent studies were focused on the mechanism of action of this Het. Because the UMSSC38 cells were found to be the most sensitive to SHetA2 among eight different HNSCC cell lines and had also shown sensitivity to Hets in vivo (21), we chose these cells for additional studies on the SHetA2 mechanism of apoptosis induction. The apoptosis was confirmed by two independent assays, the TUNEL assay and the Annexin V assay. The latter assay demonstrated also that SHetA2 was more potent than 4HPR, a potent proapoptotic retinoid (36, 37), in inducing apoptosis in the UMSSC38 cells. The exposure of these cells to SHetA2 also altered the cell cycle distribution such that the proportion of cells in the G1 phase decreased and that in the S and G2-M phases increased. There are several examples in the literature of agents that can cause cells to accumulate in G2-M and induce apoptosis. Such agents include CD437 (38), vinorelbine (39), and arsenic trioxide (40).

SHetA2 does not activate nuclear retinoid receptors in the mechanism of apoptosis induction by SHetA2 in UMSSC38 cells by demonstrating that SHetA2 increases the proportions of cells in the S phase and G2-M phase of the cell cycle in UMSSC38 cells. Cells were grown with or without 10 μM SHetA2. After 24 or 48 h, cells were harvested and analyzed using a flow cytometer for DNA contents distribution after propidium iodide staining as described in “Materials and Methods.” Results represent two independent experiments. Cells with sub-G1 DNA content were excluded from analysis by gating to obtain cell cycle distribution of cells without extensive DNA degradation.
that the pan-RAR receptor antagonist AGN193109 and the RXR antagonist LG100754 did not affect the ability of SHetA2 to kill cells. It is noteworthy that a previous study has shown that some Hets can inhibit growth of skin cell lines independently of apoptosis via a RARβ-dependent mechanism (20). The ability to induce apoptosis of head and neck cancer cells independently of receptor activation offers promise for the potential of SHetA2 to exhibit reduced toxicity/totagogenicity desired for optimal use in secondary chemoprevention strategies. In previous studies, we and others have shown that the potent apoptosis-inducing retinoid 4HPR triggers apoptosis by increasing the production of ROS in mitochondria (25, 27, 37, 41). In the present study, we have demonstrated that SHetA2 was also an effective ROS inducer, albeit less potently than 4HPR but more effectively than ATRA. The increase in ROS as well as apoptosis could be blocked by the antioxidant BHA, indicating that SHetA2-induced ROS generation is essential for apoptosis as shown for 4HPR (14, 27), as well as for various agents including tumor necrosis factor-α, transforming growth factor-β1, anti-Fas antibodies, and several chemotherapeutic agents as well as radiation (42–46). Besides increasing ROS, SHetA2 also disrupted MPTP, and this effect was blocked by CsA, which binds to Cyp-M, a cyclophilin-family protein associated with the MPTP, causing it to dissociate from the pore complex (47, 48). This reaction is believed to increase the probability of inhibiting pore flicker and lowers the binding affinity for calcium (49) and inhibits MPTP opening (50). SHetA2-induced opening of the MPTP causes release of cytochrome c into the cytoplasm presumably as a consequence of mitochondria swelling and outer membrane rupture (51, 52). The roles of ROS, MPTP, and cytochrome c in the mechanisms of SHetA2-induced apoptosis are supported by the finding that not only CsA but also another MPTP inhibitor, TFP-sensitized SHetA2 induced apoptosis.

The release of cytochrome c from the mitochondria and its interaction with cytosolic factors including Apaf-1 and dATP can activate caspase-9 and then caspase-3 (52–54). Indeed, we found that SHetA2 treatment of UMSCC38 cells resulted in activation of caspase-3 and that the caspase-3 inhibitor Ac-DEVD-CHO was able to inhibit SHetA2-induced apoptosis.

In conclusion, our results demonstrate that SHetA2 is a potent receptor-independent inducer of apoptosis and point to the mitochondria as the major mediator of this effect at least in UMSCC38 cells. Additional studies on the potential of SHetA2 for chemoprevention and therapy of ATRA-resistant cancers are warranted based on these findings and the low toxicity of SHetA2.

ACKNOWLEDGMENTS

We thank Drs. Bollag, Chandraratna, and Heyman for some of the retinoids and Drs. Carey, Reiss, and Sacks for the HNSCC cell lines.

REFERENCES


The Synthetic Heteroarotinoid SHetA2 Induces Apoptosis in Squamous Carcinoma Cells through a Receptor-independent and Mitochondria-dependent Pathway


Updated version
Access the most recent version of this article at:
http://cancerres.aacrjournals.org/content/63/13/3826

Cited articles
This article cites 51 articles, 17 of which you can access for free at:
http://cancerres.aacrjournals.org/content/63/13/3826.full#ref-list-1

Citing articles
This article has been cited by 7 HighWire-hosted articles. Access the articles at:
http://cancerres.aacrjournals.org/content/63/13/3826.full#related-urls

E-mail alerts
Sign up to receive free email-alerts related to this article or journal.

Reprints and Subscriptions
To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions
To request permission to re-use all or part of this article, use this link
http://cancerres.aacrjournals.org/content/63/13/3826.
Click on "Request Permissions" which will take you to the Copyright Clearance Center's (CCC) Rightslink site.